Research progress in C-reactive protein and the prognosis of immunotherapy for non-small cell lung cancer

doi:10.3760/cma.j.cn371439-20240805-00133

Abstract

Abstract:

Immunotherapy has become the first-line standard treatment option for driver gene-negative advanced non-small cell lung cancer （NSCLC）. But not all patients can benefit from immunotherapy， and can even have serious adverse reactions. It is crucial to identify the predictors of clinical response to immunotherapy. Several studies have shown that elevated baseline C-reactive protein （CRP） or persistent elevation of CRP during the treatment process may indicate a poorer prognosis for patients，and high CRP may be correlated with adverse reactions. Attention to the dynamic changes of CRP during immunotherapy for NSCLC may become an important predictor of prognosis.

Key words: Carcinoma， non-small cell lung, C-reactive protein, Immunotherapy, Prognosis

Fu Caihong, Xin Yuanchun, Gu Feng, Wu Yuqiang, Li Huihui, Ma Qin, Liu Xiting, Yang Lei. Research progress in C-reactive protein and the prognosis of immunotherapy for non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(12): 785-788.

References 22

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183): 1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. pmid: 30955977
[3]	Naqash AR, Stroud CRG, Butt MU, et al. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database[J]. Acta Oncol, 2018, 57(6): 867-872. DOI: 10.1080/0284186X.2017.1415460. pmid: 29241410
[4]	Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)[J]. BMC Cancer, 2020, 20(1): 1185. DOI: 10.1186/s12885-020-07690-8.
[5]	Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors[J]. Cancer Immunology Immunotherapy, 2020, 69(9): 1813-1822. DOI: 10.1007/s00262-020-02585-w.
[6]	Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia[J]. Nat Rev Dis Primers, 2018, 4: 17105. DOI: 10.1038/nrdp.2017.105. pmid: 29345251
[7]	Li W, Luo X, Liu Z, et al. Prognostic value of C-reactive protein levels in patients with bone neoplasms: a meta-analysis[J]. PLoS One, 2018, 13(4): e0195769. DOI: 10.1371/journal.pone.0195769.
[8]	Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition[J]. J Immunother Cancer, 2020, 8(1): e000842. DOI: 10.1136/jitc-2020-000842.
[9]	Li J, Duran MA, Dhanota N, et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis[J]. Cancer Discov, 2021, 11(5): 1212-1227. DOI: 10.1158/2159-8290.CD-20-0387.
[10]	Boison D, Yegutkin GG. Adenosine metabolism: emerging concepts for cancer therapy[J]. Cancer Cell, 2019, 36(6): 582-596. DOI: 10.1016/j.ccell.2019.10.007. pmid: 31821783
[11]	Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014, 515(7528): 568-571. DOI: 10.1038/nature13954.
[12]	Iivanainen S, Ahvonen J, Knuuttila A, et al. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors[J]. ESMO Open, 2019, 4(4): e000531. DOI: 10.1136/esmoopen-2019-000531.
[13]	Lindenmann J, Fink-Neuboeck N, Taucher V, et al. Prediction of postoperative clinical outcomes in resected stage Ⅰ non-small cell lung cancer focusing on the preoperative glasgow prognostic score[J]. Cancers(Basel), 2020, 12(1): 152. DOI: 10.3390/cancers12010152.
[14]	Koukourakis MI, Kambouromiti G, Pitsiava D, et al. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication[J]. Inflammation, 2009, 32(3): 169-175. DOI: 10.1007/s10753-009-9116-4. pmid: 19373547
[15]	Oya Y, Yoshida T, Kuroda H, et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer[J]. Oncotarget, 2017, 8(61): 103117-103128. DOI: 10.18632/oncotarget.21602.
[16]	Riedl JM, Barth DA, Brueckl WM, et al. C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study[J]. Cancers(Basel), 2020, 12(8): 2319. DOI: 10.3390/cancers12082319.
[17]	Inomata M, Hirai T, Seto Z, et al. Clinical parameters for predicting the survival in patients with squamous and non-squamous-cell NSCLC receiving PD-1 inhibitor therapy[J]. Pathol Oncol Res, 2020, 26(1): 327-333. DOI: 10.1007/s12253-018-0473-x. pmid: 30232703
[18]	Zheng X, Zhang L, Wu L, et al. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study[J]. BMC Cancer, 2023, 23(1): 1244. DOI: 10.1186/s12885-023-11737-x.
[19]	Schiwitza A, Schildhaus HU, Zwerger B, et al. Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer[J]. Immunotherapy, 2019, 11(9): 769-782. DOI: 10.2217/imt-2019-0039. pmid: 31120392
[20]	Suazo-Zepeda E, Bokern M, Vinke PC, et al. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis[J]. Cancer Immunol Immunother, 2021, 70(11): 3069-3080. DOI: 10.1007/s00262-021-02996-3. pmid: 34195862
[21]	Nakanishi Y, Masuda T, Yamaguchi K, et al. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer[J]. Respir Investig, 2019, 57(5): 451-459. DOI: 10.1016/j.resinv.2019.05.002. pmid: 31248832
[22]	Fukihara J, Sakamoto K, Koyama J, et al. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors[J]. Clin Lung Cancer, 2019, 20(6): 442-450, e4. DOI: 10.1016/j.cllc.2019.07.006. pmid: 31446020